ScaleUp Bio Secures Strategic Investment from Fusionopolis Ventures, Strengthening Singapore’s Role as a Regional Biomanufacturing Hub
Thursday, March 26th, 2026

ScaleUp Bio Pte Ltd has announced a new strategic investment from Fusionopolis Ventures Pte Ltd (FVPL), marking a significant step in the company’s expansion as a leading precision fermentation contract development and manufacturing organisation (CDMO) in Asia. FVPL, a subsidiary of Economic Development Innovations Singapore Pte Ltd (EDIS), will join existing partner ADM as a shareholder, reinforcing ScaleUp Bio’s growth trajectory and execution capabilities.
The partnership reflects increasing institutional confidence in precision fermentation as a critical enabler of next-generation bio-based production across multiple industries, while underscoring Singapore’s continued emergence as a hub for advanced biomanufacturing.
Strengthening Asia’s Precision Fermentation Infrastructure
ScaleUp Bio has positioned itself as Singapore’s first and largest precision fermentation CDMO, providing end-to-end capabilities from process development to pilot-scale and commercial manufacturing. Its integrated operating model is supported by a commercial pilot facility jointly operated with the A*STAR Singapore Institute of Food and Biotechnology Innovation (SIFBI), alongside consolidated industrial operations in Tuas.
This unified footprint enables a streamlined pathway for companies seeking to scale precision fermentation processes efficiently. By bridging development and commercial production, ScaleUp Bio addresses a critical infrastructure gap in the region — access to high-quality, scalable fermentation capacity.
The company’s platform supports a wide range of applications, including food and nutrition, pharmaceuticals, cosmetics, specialty chemicals and energy, reflecting the expanding industrial relevance of precision fermentation technologies.
Strategic Backing to Drive Execution and Market Access
FVPL’s investment aligns with its mandate to build high-impact biomanufacturing platforms in Asia, focusing on capability development, job creation, and industrial collaboration. By joining as a shareholder, FVPL adds further strategic depth to ScaleUp Bio’s ownership structure.
Philip Yeo, Chairman of EDIS, said: “This investment reflects our conviction in platforms that combine deep technical capability with disciplined scale-up execution. ScaleUp Bio’s CDMO platform in Singapore offers a strategic launchpad, with its regulatory strength and manufacturing ecosystem. In the same way that Singapore has become a manufacturing hub for biopharmaceuticals, I see this as the beginning of a broader regional platform designed to serve the growing biomanufacturing needs of Asia and beyond in precision fermentation.”
Enhancing Commercial Readiness and Customer Delivery
With the new investment, ScaleUp Bio is sharpening its focus on delivering integrated CDMO services for high-value bio-based specialty molecules. The consolidation of pilot and industrial capabilities within a single Singapore-based footprint is expected to reduce operational complexity and accelerate time-to-market for customers.
Aaron Yeo, General Manager of ScaleUp Bio, said: “With FVPL’s support, ScaleUp Bio will sharpen our focus as a world-class CDMO for high-value bio-based specialty molecules. With our pilot and industrial capabilities now consolidated into a single operating footprint in Singapore, we can provide a more seamless and efficient path from process development through scale-up and manufacturing. This strengthens our ability to support innovators across multiple industrial applications.”
Customers will continue to benefit from operations at ScaleUp Bio’s licensed and certified Singapore facility, now strengthened by fresh capital, aligned strategic backing and a renewed focus on execution.
Supporting the Next Phase of Asia’s Bio-based Innovation
The investment comes amid rising global demand for sustainable, bio-based production methods. As industries seek alternatives to traditional supply chains, the need for reliable and scalable fermentation infrastructure is becoming increasingly critical.
ScaleUp Bio’s expanded platform positions the company to play a key role in advancing the commercialisation of precision fermentation technologies. In doing so, it also reinforces Singapore’s strategic ambition to serve as a leading biomanufacturing hub for Asia and beyond.
SHARE WITH FRIENDS:
TAGS:








